On January 17, 2025, the Food and Drug Administration (FDA) approved datopotamab deruxtecan-dlnk a Trop-2-directed antibody ...

Having counseled thousands of patients through their breast cancer diagnosis, I was fully aware of how nondiscriminatory this ...

A landmark study overturns common beliefs about breast cancer surgery, revealing new insights into treatment choices and ...

Cite this: SABCS 2024: New Treatment Options in HR+/HER2- Breast Cancer - Medscape - Jan 10, 2025.

Breast cancer is the second leading cause of cancer death in women. Early detection results in 99% five-year survival rates.

Discover the 3 critical warning signs of breast cancer that every Black woman should know, plus insights on early detection ...

Cancer diagnoses are shifting from older to younger adults and from men to women, according to a report released Thursday by ...

Dr. Maxwell Lloyd shared the importance of improving patient access to innovative therapies like Orserdu at the 2024 San Antonio Breast Cancer Symposium.

Dr. Maxwell Lloyd discusses the long-term management of patients with HR-positive, HER2-negative breast cancer who have received Orserdu treatment.

Two new studies have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast cancer.

Researchers at the National University of Singapore (NUS) have developed a non-invasive method to improve the effectiveness ...

Dawn Klemow, MD, assistant clinical professor, University of Texas Southwestern Medical Center, previews some of the most recent advances in breast cancer treatment.